Online citations, reference lists, and bibliographies.
← Back to Search

Pleural Fluid Mesothelin As An Adjunct To The Diagnosis Of Pleural Malignant Mesothelioma

J. Creaney, A. Segal, N. Olsen, I. Dick, A. Musk, S. Skates, B. Robinson
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Rationale. The diagnosis of pleural malignant mesothelioma (MM) by effusion cytology may be difficult and is currently controversial. Effusion mesothelin levels are increased in patients with MM but the clinical role of this test is uncertain. Objectives. To determine the clinical value of measuring mesothelin levels in pleural effusion supernatant to aid diagnosis of MM. Methods and Measurements. Pleural effusion samples were collected prospectively from 1331 consecutive patients. Mesothelin levels were determined by commercial ELISA in effusions and their relationship to concurrent pathology reporting and final clinical diagnosis was determined. Results. 2156 pleural effusion samples from 1331 individuals were analysed. The final clinical diagnosis was 183 MM, 436 non-MM malignancy, and 712 nonmalignant effusions. Effusion mesothelin had a sensitivity of 67% for MM at 95% specificity. Mesothelin was elevated in over 47% of MM cases in effusions obtained before definitive diagnosis of MM was established. In the setting of inconclusive effusion cytology, effusion mesothelin had a positive predictive value of 79% for MM and 94% for malignancy. Conclusions. A mesothelin-positive pleural effusion, irrespective of the identification of malignant cells, indicates the likely presence of malignancy and adds weight to the clinical rationale for further investigation to establish a malignant diagnosis.
This paper references
10.1017/CBO9781139207249.009
I and J
William M. Marsden (2012)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
andW
R. W. Light (1972)
10.1097/PAT.0b013e32835bc848
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit
A. Segal (2013)
College of American Pathologists Committee on Nomenclature and Classification of Disease, Systematized Nomenclature of Pathology
(1965)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1002/(SICI)1097-0142(19990101)85:1<250::AID-CNCR41>3.0.CO;2-3
The use of epithelial membrane antigen and silver‐stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses
K. Metze (1999)
10.1046/j.1365-2303.2000.00247.x
Invited review The cytology of malignant mesothelioma
D. Whitaker (2000)
10.1515/9783111438443-006
N
Città DI Torino (1824)
Cancer in Western Australia: Incidence and Mortality 2003 and Mesothelioma 1960–2003, Western Australia Perth Statistical Series no. 74, Department of Health
T Threlfall (2005)
10.2307/j.ctvrnfqk1.10
? ? ? ? f ? ? ? ? ?
A. ADoefaa (2003)
10.1016/J.HUMPATH.2006.08.010
What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update.
N. Ordóñez (2007)
10.1373/clinchem.2008.121913
Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum.
K. Hollevoet (2009)
Biomarkers in pleural diseases
A. Tung (2005)
10.1016/B978-0-12-384931-1.00018-0
R
J. Lackie (2013)
10.5040/9781474284028.0024
S
A. Kumar (1824)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1378/CHEST.126.6.1721
Tumor markers in undiagnosed pleural effusions.
R. Light (2004)
10.5858/arpa.2012-0142-CR
Diffuse malignant mesothelioma.
S. Oviedo (2012)
10.1515/9783111548050-024
M
M. Sankar (1824)
The cytology of malignant mesothelioma.
D. Whitaker (2000)
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis
R. A. Stahel (2008)
Malignant mesothelioma in Australia
A. Musk (2006)
10.1016/J.LUNGCAN.2004.04.010
Epidemiology of malignant mesothelioma in Australia.
A. Musk (2004)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
10.1515/9783111413426-013
L
Il Liceo (1824)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
Glomerular filtration rate is a confounder for determination of serum soluble mesothelin
Kevin Hollevoet (2009)
10.1378/CHEST.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1179/oeh.2003.9.3.206
Malignant Mesothelioma in Australia, 1945–2002
J. Leigh (2003)
10.1016/j.lungcan.2011.01.011
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
N. Boudville (2011)
10.1111/j.1365-2559.2008.03178.x
Problems in mesothelioma diagnosis
Bruce Addis (2009)
10.7326/0003-4819-77-4-507
Pleural effusions: the diagnostic separation of transudates and exudates.
R. Light (1972)
Cancer in Western Australia: Incidence and Mortality 2003 and Mesothelioma 1960–2003
T. Threlfall (2005)
College of American Pathologists Committee on Nomenclature and Classification of Disease, Systematized Nomenclature of Pathology College of American Pathologists
(1965)
10.1016/j.clinbiochem.2009.03.007
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
B. Grigoriu (2009)
and E
A. A. Renshaw (1997)
and T
S. Yamada (2011)
10.1093/ANNONC/MDM027
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
C. Manegold (2007)
10.1016/j.medcli.2008.11.047
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
C. Alemán (2009)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1515/CCLM.2011.242
Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma
S. Yamada (2011)
and D
K. D. Wolanski (1998)
and Y
A. Tung (2011)



This paper is referenced by
10.4225/23/5976d9b9cabf2
The diagnostic potential and biological significance of MicroRNA in Malignant Pleural Mesothelioma
Kimberly A. Birnie (2016)
10.1007/s13402-017-0327-7
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
Nick Beije (2017)
10.1371/journal.pone.0185850
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
Takehiro Otoshi (2017)
10.1093/ije/dyz204
The Wittenoom legacy.
Arthur W Bill Musk (2019)
10.1586/17476348.2015.1098535
The diagnosis of pleural effusions
J. M. Porcel (2015)
10.1183/16000617.0019-2016
Malignant pleural effusion: from bench to bedside
I. Psallidas (2016)
Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention.
A. Izzotti (2016)
10.1136/bmjresp-2017-000270
Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)
D. de Fonseka (2018)
10.1097/MD.0000000000014979
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma
Ruiyue Gao (2019)
10.1016/j.jtho.2018.06.011
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
L. Mutti (2018)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1155/2019/8628612
MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
Kimberly A. Birnie (2019)
BIBLIOGRAPHIC REVIEW July 2016 Third Consensus Conference on Malignant Pleural Mesothelioma: State-of-the-art and recommendations
(2016)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1177/1753465816671697
Current best practice in the evaluation and management of malignant pleural effusions
S. Walker (2017)
10.1097/MCP.0000000000000167
Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma
J. Creaney (2015)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
Semantic Scholar Logo Some data provided by SemanticScholar